文献速递免疫规划传染病防控与疫情报告

肌内注射CS6亚单位疫苗联合dmLT佐剂的安全性及免疫原性

Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.
PubMed 文献 · Vaccine · 2021-08-18

开放标签试验中,50名受试者分别接受CssBA单用、dmLT单用或不同剂量CssBA联合dmLT肌内注射三次。疫苗安全耐受,无疫苗相关严重不良事件,诱导剂量依赖性抗体反应,显示dmLT佐剂效应。

要点

  • CssBA联合dmLT肌内注射安全耐受,无疫苗相关严重不良事件。
  • 抗体反应呈剂量依赖性,dmLT佐剂效应明确。
  • 45μg CssBA+0.5μg dmLT组各检测方法应答率50%至100%。

核心结论

  • CssBA和/或dmLT肌内注射安全且具免疫原性,联合使用诱导对CS6和LT的稳健免疫应答。

研究设计与样本

  • 开放标签试验,50名受试者接受三次肌内注射(第1、22、43天),分组包括CssBA单用5μg、dmLT单用0.1μg及CssBA(5、15、45μg)联合dmLT(0.1和0.5μg)。

主要发现

  • 所有剂量组疫苗安全耐受,无疫苗相关严重或重度不良事件。
  • 疫苗相关不良事件中98%为轻度,79%为短暂接种部位反应。
  • 抗体反应呈剂量依赖性,dmLT佐剂效应明确。
  • 接受45μg CssBA和0.5μg dmLT的受试者应答率在各检测方法中为50%至100%。

临床怎么用

  • 支持进一步评估该疫苗靶点的效力并开发多价亚单位ETEC疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Enterotoxigenic Escherichia coli (ETEC) is a common cause of infectious diarrhoea and a leading cause of morbidity and mortality in children living in resource-limited settings. It is also the leading cause of travellers' diarrhoea among civilian and military travellers. Its dual importance in global public health and travel medicine highlights the need for an effective vaccine. ETEC express colonization factors (CFs) that mediate adherence to the small intestine. An epidemiologically prevalent CF is coli surface antigen 6 (CS6). We assessed the safety and immunogenicity of a CS6-targeted candidate vaccine, CssBA, co-administered intramuscularly with the double-mutant heat-labile enterotoxin, dmLT [LT(R192G/L211A)]. METHODS: This was an open-label trial. Fifty subjects received three intramuscular injections (Days 1, 22 and 43) of CssBA alone (5 µg), dmLT alone (0.1 µg) or CssBA (5, 15, 45 µg) + dmLT (0.1 and 0.5 µg). Subjects were actively monitored for adverse events for 28 days following the third vaccination. Antibody responses (IgG and IgA) were characterized in the serum and from lymphocyte supernatants (ALS) to CS6 and the native ETEC heat labile enterotoxin, LT. RESULTS: Across all dose cohorts, the vaccine was safe and well-tolerated with no vaccine-related severe or serious adverse events. Among vaccine-related adverse events, a majority (98%) were mild with 79% being short-lived vaccine site reactions. Robust antibody responses were induced in a dose-dependent manner with a clear dmLT adjuvant effect. Response rates in subjects receiving 45 µg CssBA and 0.5 µg dmLT ranged from 50 to 100% across assays. CONCLUSION: This is the first study to demonstrate the safety and immunogenicity of CssBA and/or dmLT administered intramuscularly. Co-administration of the two components induced robust immune responses to CS6 and LT, paving the way for future studies to evaluate the efficacy of this vaccine target and development of a multivalent, subunit ETEC vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee T, Gutiérrez RL, Maciel M, et al. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine. 2021. PMID: 34419306. doi:10.1016/j.vaccine.2021.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。